Nkarta, Inc.

NasdaqGS NKTX

Nkarta, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 14.79

Nkarta, Inc. Price to Sales Ratio (P/S) is 14.79 on January 14, 2025, a -63.09% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Nkarta, Inc. 52-week high Price to Sales Ratio (P/S) is 72.45 on March 06, 2024, which is 389.76% above the current Price to Sales Ratio (P/S).
Nkarta, Inc. 52-week low Price to Sales Ratio (P/S) is 14.53 on December 18, 2024, which is -1.81% below the current Price to Sales Ratio (P/S).
Nkarta, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 37.68.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: NKTX

Nkarta, Inc.

CEO	Mr. Paul J. Hastings
IPO Date	July 10, 2020
Location	United States
Headquarters	6000 Shoreline Court
Employees	159
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Key trends

Past 5 years